Compare Plby Group Inc (PLBY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs ResMed Inc. — how do they compare? Plby Group Inc trades at $0.98 (market cap $118.21M), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 269.8× Plby Group Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and ResMed Inc. for 51 Days on average.
| PLBY | RMD | |
|---|---|---|
Market Cap | $118.21M | $31.89B |
Volume | 919,783 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $277.88 |
52-Week Low | $0.99 | $182.82 |
Typical Hold Time | 24 Days | 51 Days |
Enterprise Value | $263.80M | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $0.97, down 4.5% today, with a bearish technical outlook despite analyst optimism. The company shows improving fundamentals with revenue stabilizing around $120M and narrowing losses, though it remains unprofitable with negative equity. Recent leadership appointments signal strategic focus on brand growth and licensing expansion.
The stock presents a turnaround opportunity with strong analyst support (75% buy ratings) but carries significant risk from high debt levels and negative shareholder equity. Near-term catalysts depend on execution of the media and experiences strategy, while competitive pressures and cash flow volatility remain concerns.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
